Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Feasibility and initial outcomes of a multifaceted prevention programme of melioidosis in diabetic patients in Ubon Ratchathani, northeast Thailand.

Suntornsut P, Chaowagul W, Thongklang W, Phosri T, Day NPJ, Michie S, Limmathurotsakul D.

PLoS Negl Trop Dis. 2018 Sep 6;12(9):e0006765. doi: 10.1371/journal.pntd.0006765. eCollection 2018 Sep.

2.

Loss-of-function mutations of SCN10A encoding NaV1.8 α subunit of voltage-gated sodium channel in patients with human kidney stone disease.

Nettuwakul C, Praditsap O, Sawasdee N, Rungroj N, Ruamyod K, Watanapa WB, Junking M, Sangnual S, Sritippayawan S, Cheunsuchon B, Chuawattana D, Rojsatapong S, Chaowagul W, Dib-Hajj SD, Waxman SG, Yenchitsomanus PT.

Sci Rep. 2018 Jul 11;8(1):10453. doi: 10.1038/s41598-018-28623-3.

3.

Melioidosis in Thailand: Present and Future.

Hinjoy S, Hantrakun V, Kongyu S, Kaewrakmuk J, Wangrangsimakul T, Jitsuronk S, Saengchun W, Bhengsri S, Akarachotpong T, Thamthitiwat S, Sangwichian O, Anunnatsiri S, Sermswan RW, Lertmemongkolchai G, Tharinjaroen CS, Preechasuth K, Udpaun R, Chuensombut P, Waranyasirikul N, Anudit C, Narenpitak S, Jutrakul Y, Teparrukkul P, Teerawattanasook N, Thanvisej K, Suphan A, Sukbut P, Ploddi K, Sirichotirat P, Chiewchanyon B, Rukseree K, Hongsuwan M, Wongsuwan G, Sunthornsut P, Wuthiekanun V, Sachaphimukh S, Wannapinij P, Chierakul W, Chewapreecha C, Thaipadungpanit J, Chantratita N, Korbsrisate S, Taunyok A, Dunachie S, Palittapongarnpim P, Sirisinha S, Kitphati R, Iamsirithaworn S, Chaowagul W, Chetchotisak P, Whistler T, Wongratanacheewin S, Limmathurotsakul D.

Trop Med Infect Dis. 2018;3(2):38. doi: 10.3390/tropicalmed3020038. Epub 2018 Apr 8.

4.

Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Chetchotisakd P, Chierakul W, Chaowagul W, Anunnatsiri S, Phimda K, Mootsikapun P, Chaisuksant S, Pilaikul J, Thinkhamrop B, Phiphitaporn S, Susaengrat W, Toondee C, Wongrattanacheewin S, Wuthiekanun V, Chantratita N, Thaipadungpanit J, Day NP, Limmathurotsakul D, Peacock SJ.

Lancet. 2014 Mar 1;383(9919):807-14. doi: 10.1016/S0140-6736(13)61951-0. Epub 2013 Nov 25.

5.

Prospective observational study of the frequency and features of intra-abdominal abscesses in patients with melioidosis in northeast Thailand.

Maude RR, Vatcharapreechasakul T, Ariyaprasert P, Maude RJ, Hongsuwan M, Yuentrakul P, Limmathurotsakul D, Koh GC, Chaowagul W, Day NP, Peacock SJ.

Trans R Soc Trop Med Hyg. 2012 Oct;106(10):629-31. doi: 10.1016/j.trstmh.2012.05.007. Epub 2012 Jul 7.

6.

Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Wuthiekanun V, Amornchai P, Saiprom N, Chantratita N, Chierakul W, Koh GC, Chaowagul W, Day NP, Limmathurotsakul D, Peacock SJ.

Antimicrob Agents Chemother. 2011 Nov;55(11):5388-91. doi: 10.1128/AAC.05517-11. Epub 2011 Aug 29.

7.

Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis.

Suwannasaen D, Mahawantung J, Chaowagul W, Limmathurotsakul D, Felgner PL, Davies H, Bancroft GJ, Titball RW, Lertmemongkolchai G.

J Infect Dis. 2011 Apr 1;203(7):1002-11. doi: 10.1093/infdis/jiq142. Epub 2011 Feb 7.

8.

Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis.

Koh GC, Maude RR, Schreiber MF, Limmathurotsakul D, Wiersinga WJ, Wuthiekanun V, Lee SJ, Mahavanakul W, Chaowagul W, Chierakul W, White NJ, van der Poll T, Day NP, Dougan G, Peacock SJ.

Clin Infect Dis. 2011 Mar 15;52(6):717-25. doi: 10.1093/cid/ciq192. Epub 2011 Feb 3.

9.

Increasing incidence of human melioidosis in Northeast Thailand.

Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Chaowagul W, Day NP, Peacock SJ.

Am J Trop Med Hyg. 2010 Jun;82(6):1113-7. doi: 10.4269/ajtmh.2010.10-0038.

10.

Patterns of organ involvement in recurrent melioidosis.

Limmathurotsakul D, Chaowagul W, Day NP, Peacock SJ.

Am J Trop Med Hyg. 2009 Aug;81(2):335-7.

11.

Rheumatological manifestations in patients with melioidosis.

Teparrakkul P, Tsai JJ, Chierakul W, Gerstenmaier JF, Wacharaprechasgu T, Piyaphanee W, Limmathurotsakul D, Chaowagul W, Day NP, Peacock SJ.

Southeast Asian J Trop Med Public Health. 2008 Jul;39(4):649-55.

PMID:
19058601
12.

A simple scoring system to differentiate between relapse and re-infection in patients with recurrent melioidosis.

Limmathurotsakul D, Chaowagul W, Chantratita N, Wuthiekanun V, Biaklang M, Tumapa S, White NJ, Day NP, Peacock SJ.

PLoS Negl Trop Dis. 2008;2(10):e327. doi: 10.1371/journal.pntd.0000327. Epub 2008 Oct 29.

13.

Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis.

Cheng AC, Chierakul W, Chaowagul W, Chetchotisakd P, Limmathurotsakul D, Dance DA, Peacock SJ, Currie BJ.

Am J Trop Med Hyg. 2008 Feb;78(2):208-9.

14.

Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit.

Chierakul W, Anunnatsiri S, Chaowagul W, Peacock SJ, Chetchotisakd P, Day NP.

Clin Infect Dis. 2007 Aug 15;45(4):521-3. No abstract available.

PMID:
17638209
15.

Variable presentation of neurological melioidosis in Northeast Thailand.

Limmathurotsakul D, Chaowagul W, Wongsrikaew P, Narmwong A, Day NP, Peacock SJ.

Am J Trop Med Hyg. 2007 Jul;77(1):118-20.

PMID:
17620641
16.

A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand.

Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Wuthiekanun V, Stephens DP, Day NP, White NJ, Chaowagul W, Currie BJ, Peacock SJ.

Clin Infect Dis. 2007 Aug 1;45(3):308-14. Epub 2007 Jun 15.

PMID:
17599307
17.

Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis.

Chierakul W, Wangboonskul J, Singtoroj T, Pongtavornpinyo W, Short JM, Maharjan B, Wuthiekanun V, Dance DA, Teparrukkul P, Lindegardh N, Peacock SJ, Day NP, Chaowagul W, White NJ.

J Antimicrob Chemother. 2006 Dec;58(6):1215-20. Epub 2006 Sep 26.

PMID:
17003061
18.

Risk factors for recurrent melioidosis in northeast Thailand.

Limmathurotsakul D, Chaowagul W, Chierakul W, Stepniewska K, Maharjan B, Wuthiekanun V, White NJ, Day NP, Peacock SJ.

Clin Infect Dis. 2006 Oct 15;43(8):979-86. Epub 2006 Sep 1.

PMID:
16983608
19.

Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand.

Wuthiekanun V, Chierakul W, Langa S, Chaowagul W, Panpitpat C, Saipan P, Thoujaikong T, Day NP, Peacock SJ.

Am J Trop Med Hyg. 2006 Jun;74(6):1074-5.

PMID:
16760522
20.

Meticillin-resistant Staphylococcus aureus in rural Asia.

Nickerson EK, Wuthiekanun V, Day NP, Chaowagul W, Peacock SJ.

Lancet Infect Dis. 2006 Feb;6(2):70-1. No abstract available.

PMID:
16439325
21.

Short report: disease severity and outcome of melioidosis in HIV coinfected individuals.

Chierakul W, Wuthiekanun V, Chaowagul W, Amornchai P, Cheng AC, White NJ, Day NP, Peacock SJ.

Am J Trop Med Hyg. 2005 Dec;73(6):1165-6.

PMID:
16354832
22.

Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse.

Maharjan B, Chantratita N, Vesaratchavest M, Cheng A, Wuthiekanun V, Chierakul W, Chaowagul W, Day NP, Peacock SJ.

J Clin Microbiol. 2005 Dec;43(12):6032-4.

23.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr.

Int J Infect Dis. 2006 Jan;10(1):25-31. Epub 2005 Nov 11.

24.

The role and significance of sputum cultures in the diagnosis of melioidosis.

Huis in 't Veld D, Wuthiekanun V, Cheng AC, Chierakul W, Chaowagul W, Brouwer AE, White NJ, Day NP, Peacock SJ.

Am J Trop Med Hyg. 2005 Oct;73(4):657-61.

PMID:
16222004
25.

Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis.

Chaowagul W, Chierakul W, Simpson AJ, Short JM, Stepniewska K, Maharjan B, Rajchanuvong A, Busarawong D, Limmathurotsakul D, Cheng AC, Wuthiekanun V, Newton PN, White NJ, Day NP, Peacock SJ.

Antimicrob Agents Chemother. 2005 Oct;49(10):4020-5.

26.

Prospective evaluation of a rapid immunochromogenic cassette test for the diagnosis of melioidosis in northeast Thailand.

Cheng AC, Peacock SJ, Limmathurotsakul D, Wongsuvan G, Chierakul W, Amornchai P, Getchalarat N, Chaowagul W, White NJ, Day NP, Wuthiekanun V.

Trans R Soc Trop Med Hyg. 2006 Jan;100(1):64-7. Epub 2005 Sep 15.

PMID:
16168447
27.

Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis.

Chierakul W, Anunnatsiri S, Short JM, Maharjan B, Mootsikapun P, Simpson AJ, Limmathurotsakul D, Cheng AC, Stepniewska K, Newton PN, Chaowagul W, White NJ, Peacock SJ, Day NP, Chetchotisakd P.

Clin Infect Dis. 2005 Oct 15;41(8):1105-13. Epub 2005 Sep 2.

PMID:
16163628
28.

Antibodies from patients with melioidosis recognize Burkholderia mallei but not Burkholderia thailandensis antigens in the indirect hemagglutination assay.

Tiyawisutsri R, Peacock SJ, Langa S, Limmathurotsakul D, Cheng AC, Chierakul W, Chaowagul W, Day NP, Wuthiekanun V.

J Clin Microbiol. 2005 Sep;43(9):4872-4.

29.

Melioidosis in 6 tsunami survivors in southern Thailand.

Chierakul W, Winothai W, Wattanawaitunechai C, Wuthiekanun V, Rugtaengan T, Rattanalertnavee J, Jitpratoom P, Chaowagul W, Singhasivanon P, White NJ, Day NP, Peacock SJ.

Clin Infect Dis. 2005 Oct 1;41(7):982-90. Epub 2005 Sep 1.

PMID:
16142663
30.

Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei.

Wuthiekanun V, Cheng AC, Chierakul W, Amornchai P, Limmathurotsakul D, Chaowagul W, Simpson AJ, Short JM, Wongsuvan G, Maharjan B, White NJ, Peacock SJ.

J Antimicrob Chemother. 2005 Jun;55(6):1029-31. Epub 2005 May 10.

PMID:
15886263
31.

Role and significance of quantitative urine cultures in diagnosis of melioidosis.

Limmathurotsakul D, Wuthiekanun V, Chierakul W, Cheng AC, Maharjan B, Chaowagul W, White NJ, Day NP, Peacock SJ.

J Clin Microbiol. 2005 May;43(5):2274-6.

32.

The changing pattern of bloodstream infections associated with the rise in HIV prevalence in northeastern Thailand.

Chierakul W, Rajanuwong A, Wuthiekanun V, Teerawattanasook N, Gasiprong M, Simpson A, Chaowagul W, White NJ.

Trans R Soc Trop Med Hyg. 2004 Nov;98(11):678-86.

PMID:
15363648
33.

Diabetes mellitus, insulin, and melioidosis in Thailand.

Simpson AJ, Newton PN, Chierakul W, Chaowagul W, White NJ.

Clin Infect Dis. 2003 Mar 1;36(5):e71-2. Epub 2003 Feb 12.

PMID:
12594658
34.

Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline.

Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B.

Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2):24-7.

PMID:
11425157
35.

Protein and energy metabolism in chronic bacterial infection: studies in melioidosis.

Paton NI, Angus B, Chaowagul W, Simpson AJ, Suputtamongkol Y, Elia M, Calder G, Milne E, White NJ, Griffin GE.

Clin Sci (Lond). 2001 Jan;100(1):101-10.

PMID:
11115424
36.

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ.

Br J Clin Pharmacol. 2000 Aug;50(2):184-91.

37.

Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria.

Lauw FN, Simpson AJ, Hack CE, Prins JM, Wolbink AM, van Deventer SJ, Chaowagul W, White NJ, van Der Poll T.

J Infect Dis. 2000 Jul;182(1):206-13. Epub 2000 Jul 6.

PMID:
10882599
38.

The CXC chemokines gamma interferon (IFN-gamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis.

Lauw FN, Simpson AJ, Prins JM, van Deventer SJ, Chaowagul W, White NJ, van der Poll T.

Infect Immun. 2000 Jul;68(7):3888-93.

39.

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ.

Br J Clin Pharmacol. 2000 May;49(5):445-52. Corrected and republished in: Br J Clin Pharmacol. 2000 Aug;50(2):184-91.

40.

Differential antibiotic-induced endotoxin release in severe melioidosis.

Simpson AJ, Opal SM, Angus BJ, Prins JM, Palardy JE, Parejo NA, Chaowagul W, White NJ.

J Infect Dis. 2000 Mar;181(3):1014-9.

PMID:
10720525
41.

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ.

Antimicrob Agents Chemother. 2000 Mar;44(3):693-6.

42.

Recent advances in the treatment of severe melioidosis.

Chaowagul W.

Acta Trop. 2000 Feb 5;74(2-3):133-7. Review.

PMID:
10674641
43.

Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis.

Simpson AJ, Smith MD, Weverling GJ, Suputtamongkol Y, Angus BJ, Chaowagul W, White NJ, van Deventer SJ, Prins JM.

J Infect Dis. 2000 Feb;181(2):621-5.

PMID:
10669346
44.

Antilipopolysaccharide II: an antibody protective against fatal melioidosis.

Charuchaimontri C, Suputtamongkol Y, Nilakul C, Chaowagul W, Chetchotisakd P, Lertpatanasuwun N, Intaranongpai S, Brett PJ, Woods DE.

Clin Infect Dis. 1999 Oct;29(4):813-8.

PMID:
10589895
45.

Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis.

Lauw FN, Simpson AJ, Prins JM, Smith MD, Kurimoto M, van Deventer SJ, Speelman P, Chaowagul W, White NJ, van der Poll T.

J Infect Dis. 1999 Dec;180(6):1878-85.

PMID:
10558944
46.

Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe meliodosis.

Nuntayanuwat S, Dharakul T, Chaowagul W, Songsivilai S.

Hum Immunol. 1999 Oct;60(10):979-83.

PMID:
10566599
47.

Risk factors for melioidosis and bacteremic melioidosis.

Suputtamongkol Y, Chaowagul W, Chetchotisakd P, Lertpatanasuwun N, Intaranongpai S, Ruchutrakool T, Budhsarawong D, Mootsikapun P, Wuthiekanun V, Teerawatasook N, Lulitanond A.

Clin Infect Dis. 1999 Aug;29(2):408-13.

PMID:
10476750
48.

Comparison of imipenem and ceftazidime as therapy for severe melioidosis.

Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, Rajanuwong A, Wuthiekanun V, Howe PA, Walsh AL, Chaowagul W, White NJ.

Clin Infect Dis. 1999 Aug;29(2):381-7.

PMID:
10476746
49.

A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis.

Chaowagul W, Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, White NJ.

Clin Infect Dis. 1999 Aug;29(2):375-80.

PMID:
10476745
50.

Empirical cephalosporin treatment of melioidosis.

Chaowagul W, Simpson AJ, Suputtamongkol Y, White NJ.

Clin Infect Dis. 1999 Jun;28(6):1328. No abstract available.

PMID:
10451181

Supplemental Content

Loading ...
Support Center